# A Phase I/IIa Study of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration

Source: https://onco.cc/trials/nct06959615/  
OnCo record `nct06959615` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of JAB-23E73 in advanced solid tumours, run by Jacobio Pharmaceuticals Co., Ltd., now recruiting.

## Summary

A Phase I/IIa Study of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration is a phase 1/2 interventional study registered as NCT06959615 by Jacobio Pharmaceuticals Co., Ltd., with 334 participants planned, started 2024-11-22 and due to reach its primary completion in 2026-12-31. Interventions recorded: JAB-23E73.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06959615
- Phase: 1/2
- Setting: A Multicenter, Open Phase I/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration
- Sponsor: Jacobio Pharmaceuticals Co., Ltd.
- Enrolled: 334

## Sources

- ClinicalTrials.gov NCT06959615: https://clinicaltrials.gov/study/NCT06959615

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- companies: [Jacobio Pharmaceuticals](https://onco.cc/companies/jacobio-pharmaceuticals/)

---
JSON: https://onco.cc/api/v1/entities/nct06959615.json